Eli Lilly to Highlight P-III (BRUIN CLL-321) Trial Data of Jaypirca (Pirtobrutinib) for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma at ASH 2024
Shots:
- The P-III (BRUIN CLL-321) study assessed Jaypirca (200mg, QD) vs idelalisib + rituximab (IdelaR) or bendamustine + rituximab (BR) in CLL/SLL patients (n=238), treated with BTK inhibitor
- Results (by IRC evaluation), showed a 46% reduction in disease progression or death risk, mPFS of 14 vs 8.7mos. & consistent PFS benefits in poor-prognosis subgroups at 19mos. follow-up. Improvement in investigator-assessed PFS (mPFS: 15.3 vs 9.2mos.), EFS (mEFS: 14.1 vs 7.6mos.) & time to next treatment (23.9 vs 10.9mos.) was also observed
- In addition, Jaypirca has the US FDA’s accelerated approval for CLL/SLL or r/r MCL after at least two prior therapies, incl. a BTK inhibitor. Full approval depends on confirmatory trial
Ref: Eli Lilly | Image: Eli Lilly
Related News:- Eli Lilly Reports Results from the P-IIIb (SURMOUNT-5) Trial of Zepbound (Tirzepatide) in Obese Adults
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
